Close this search box.

We are creating some awesome events for you. Kindly bear with us.

Hong Kong company announces full chain of enzymatic technologies for bio-manufacturing

According to a recent report, a Hong Kong Science and Technology Parks Corporation (HKSTP) partner company since 2007, announced that it has developed a leading comprehensive biotechnology platform that applies enzyme-based, low-cost processes in manufacturing high-quality pharmaceutical, nutraceutical and food products.

The company is currently one of the only companies in the world that have a complete chain of enzymatic production with advanced technology in each of the manufacturing steps.

Named Immobilised Enzyme Assembly for Cascade Biocatalysis, the biotech platform uses newly-developed industrial enzymes, proprietary technologies and ground-breaking enzyme-based manufacturing processes to develop drugs and food ingredients for various industries.

The technologies, industrial processes, including the products manufactured using these processes, have been validated by international standards bodies such as the American, EU and Japanese Pharmacopeia.

The company has also signed partnership agreements with the leaders in the pharmaceutical and nutritional industries to apply their proprietary technologies for mass production.

Earlier this year, the company opened a new 3,000 square feet laboratory in addition to its current facilities in Hong Kong Science Park. This laboratory serves as the main R&D facility staffed by more than 30 research scientists, with many of them holding advanced degrees in various relevant disciplines. The laboratory focuses on transforming laboratory techniques and technologies into commercial and industrial applications. GeneHarbor also has manufacturing facilities in Shanghai, Suzhou and Ningbo, China.

 Enzyme-based Processes to Disrupt Conventional Methods in Bio-manufacturing

Enzymes and the accompanying co-enzymes are biocatalysts that are often used in the manufacture of drugs and health products. Currently, of the HK$23.4 trillion (US$3 trillion) worth of fine chemicals produced annually, only less than 4 per cent are made by enzymatic processes.

“Green chemistry” is playing an increasingly important role in the manufacturing industry, and as such, enzyme-based manufacturing methods are much preferred by industry players. This new approach is set to revolutionise bio-manufacturing because they are highly specific in producing the final products with high yields, generating less waste and by-products.

The reactions take place under mild conditions and usually do not use other potentially-polluting chemicals or require high temperatures and high pressures used in conventional chemical manufacturing processes. Enzymes are also non-toxic and biodegradable.

The Founder and CEO of the company stated that the current methods of applying enzymatic processes in industrial manufacturing are not common because enzymes and co-enzymes are very expensive. Furthermore, the bio-reactors in use today are not efficient.

He noted that after more than twenty years of research and over HK$1.17 billion (US$150 million) invested into exploring new enzymes, developing proprietary and patented technologies never used before in the industry, the company has established over a dozen new processes of producing pharmaceutical and food products and is on the cusp of completely revolutionising the bio-manufacturing industry.

The company’s manufacturing innovations have already positively impacted the nutritional market, making some of the previously expensive products more affordable to the public. One example is β-Nicotinamide mononucleotide (NMN), an anti-aging product.

Over the last two years, the company’s manufacturing methods have reduced the retail price of an NMN 9000 capsule from HK$23,400 (US$3,000) to less than HK$1,560 (US$200) today.

For another product, the natural antioxidant glutathione (GSH), the company’s manufacturing innovations have reduced solid waste and energy consumption by over 70 per cent, compared to conventional processes.

HKSTP has been supported the local development of Hong Kong’s innovation & Technology (I&T) sector, and biomedical research is one of its key focus areas. Hong Kong Science Park currently has one of the most vibrant biomedical technology ecosystems, with more than 100 biotechnology companies involved in medical devices, molecular diagnosis, stem cell therapy, regenerative medicine, traditional Chinese medicine and advanced therapeutics.

The Biomedical Technology Support Centre at Science Park provides R&D tools and affordable high-quality technical services for local research, especially for start-ups.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.